Marker Therapeut Stock Price, News & Analysis

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has announced its participation in Canaccord Genuity's Horizons in Oncology Virtual Conference. CEO Dr. Juan Vera will join a panel discussion titled 'CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?' scheduled for April 7, 2025, from 11:00 AM to 11:50 AM ET.

The company specializes in developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. Their innovative platform features multi antigen recognizing (MAR)-T cell therapy, designed to simultaneously target multiple tumor-associated antigens. This approach has demonstrated promising clinical results in both hematologic malignancies and solid tumors.

Marker Therapeutics (MRKR) reported its 2024 year-end results, highlighting significant progress in its lead program MT-601. The company's Phase 1 APOLLO study demonstrated promising results with a 78% objective response rate in lymphoma patients, including 44.4% complete responses. The therapy showed a favorable safety profile with minimal side effects.

MRKR secured $13 million in non-dilutive funding from CPRIT and NIH SBIR, and raised $16.1 million through a private placement. The company ended 2024 with $19.2 million in cash, expecting to fund operations into Q1 2026. Financial results showed R&D expenses of $13.5 million (up from $10.4M in 2023) and a net loss of $10.7 million (compared to $8.2M in 2023).

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced that its President and CEO, Dr. Juan Vera, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This event will take place on February 25, 2025.

Dr. Vera is scheduled to present an overview of Marker’s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Registered participants can access the presentation through the event portal on the day of the event.

Marker Therapeutics (MRKR) has secured a $16.1 million private placement through the sale of 5,031,250 shares of common stock and accompanying warrants. The financing, priced at $3.20 per share, includes participation from Blue Owl Healthcare Opportunities, NEA, and Aisling Capital.

The proceeds will primarily support the clinical advancement of the company's Phase 1 APOLLO study investigating MT-601, a multi-antigen recognizing T cell product, in lymphoma patients who have relapsed after anti-CD19 CAR-T cell therapy or where such therapy isn't an option.

The warrants will be exercisable upon shareholder approval with a five-year term and an exercise price of $4.03 per share. Canaccord Genuity leads the placement with Brookline Capital Markets as co-placement agent.

Marker Therapeutics (MRKR) reported positive clinical updates from its Phase 1 APOLLO study of MT-601 in lymphoma patients. The study showed 78% objective response rates with 44.4% complete response in patients who relapsed after anti-CD19 CAR-T therapy or where CAR-T wasn't an option. Out of 10 treated patients, data is available for 9 participants from 5 U.S. clinical sites.

MT-601 demonstrated strong safety profile with no immune-effector cell associated neurotoxicity syndrome (ICANS) and only one Grade 1 cytokine release syndrome case. Long-term follow-up data of 6-12 months is available for three patients, with ongoing monitoring for response durability. The treatment showed efficacy in heavily pre-treated patients who had received 3-12 prior lines of therapy.

Marker Therapeutics (MRKR) has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support clinical investigation of MT-601 in metastatic pancreatic cancer patients. The grant will fund the Phase 1 PANACEA study evaluating safety and tolerability of their multi-tumor associated antigen T cell product.

MT-601 is currently being studied in CD19-CAR relapsed lymphoma patients, with preliminary data showing sustained objective responses in three participants. The therapy targets six tumor-specific antigens and shows promise beyond lymphoma. Previous studies at Baylor College of Medicine using similar technology showed favorable results in pancreatic cancer patients, with 1 complete response, 3 partial responses, and 6 stable disease cases out of 13 patients.

Including this grant, MRKR has secured over $30 million in non-dilutive funding, including an additional $2 million NIH SBIR grant for pancreatic cancer research. The company plans to initiate the pancreatic cancer clinical program in 2025.

Marker Therapeutics (MRKR), a clinical-stage immuno-oncology company, announced its participation in the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. Juan Vera, M.D., President and CEO, will present on December 12, 2024, at 1:30 PM EST.

The presentation will showcase Marker's technology and clinical developments in T cell-based immunotherapies for treating hematological malignancies and solid tumor indications. Registered participants can access the presentation through the event portal, and a replay will be available on the Company's IR website under Events & Presentations.